New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera in Early-Stage Breast Cancer Patients
Austin, Texas - Natera, Inc. (NASDAQ: NTRA), a leading company in cell-free DNA and genetic testing, has released a new publication in JCO Precision Oncology providing compelling evidence of the effectiveness of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, in detecting recurrence at an early stage in patients with early-stage breast cancer. The full study can be accessed here, giving readers valuable insights into the study’s findings.
The study analyzed a total of 1,136 plasma samples that were prospectively collected and stored from 156 patients with early-stage breast cancer. The Signatera MRD test was applied to these samples to evaluate its accuracy and effectiveness in detecting the presence of residual disease and predicting early recurrence.
Results from the study demonstrated that Signatera identified MRD in 29% (45 out of 156) of the patients’ samples before clinical recurrence could be detected using standard imaging techniques. This early detection allowed for immediate intervention and timely treatment, potentially improving patient outcomes and reducing mortality rates associated with breast cancer recurrence.
Detecting MRD is crucial in predicting the likelihood of disease recurrence and tailoring treatment strategies based on individual patients’ risk profiles. Traditional monitoring methods often involve clinical imaging, such as mammography or ultrasound, but these methods may not detect microscopic residual disease. By using Signatera, a highly sensitive and specific MRD test, clinicians can identify circulating tumor DNA (ctDNA) in blood samples, which serves as an essential indicator of minimal residual disease and the potential for recurrence.
The Signatera MRD test offers several advantages over traditional monitoring approaches. Firstly, it provides more accurate and reliable results compared to imaging techniques alone, enabling clinicians to detect cancer earlier. Secondly, it offers a personalized approach, as it can detect individualized mutations specific to each patient’s tumor, making it suitable for personalized follow-up care. Lastly, the ease and convenience of a blood draw, compared to invasive imaging procedures, make it a patient-friendly option.
Dr. David Craik, Senior Vice President of Clinical Affairs and Medical Director at Natera, emphasized the importance of extended surveillance in breast cancer patients. He explained, Our study reinforces the potential benefits of integrating Signatera into standard surveillance protocols for patients with early-stage breast cancer. Early detection of minimal residual disease using Signatera has the potential to improve patient outcomes by providing an opportunity for early intervention and tailored treatment strategies.
The findings from this study contribute to an increasing body of evidence supporting the usage of Signatera as an effective MRD test. Natera’s commitment to ongoing research and development in this field is aimed at improving personalized treatment options and long-term patient outcomes.
In conclusion, the publication of this study showcasing the ability of Signatera to detect recurrence early in early-stage breast cancer patients is a significant development in the field of cancer surveillance. The findings of this extensive evaluation provide valuable insights into the effectiveness of Signatera as an MRD test. This study reinforces the importance of extended surveillance and personalized treatment strategies to improve patient outcomes. Natera’s ongoing commitment to research and development highlights their dedication to advancing the field of precision medicine in cancer care.
Comments